© 2023 MJH Life Sciences and Managed Healthcare Executive. All rights reserved.
© 2023 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.
November 23, 2022
Payers are bracing themselves for more ultra-expensive gene therapies.
November 21, 2022
German researchers developed a modified adeno-associated virus capsid that has greater affinity for liver cells.
November 17, 2022
Enyzyre says its at-home testing system will be a major advance for people with hemophilia because they will better able to manage the disease on their own.
CSL Behring's gene therapy, called EntranaDez, may be approved later this month. BioMarin, Pfizer, Bayer and Freeline Therapeutics also have gene therapies for hemophilia in development.
October 04, 2022
The hemophilia organization developed a shared decision-making tool for patients and providers.
Long-acting recombinant replacement factor gets favorable rating from multidisciplinary group. Gene therapy was viewed with some wariness.
September 21, 2022
Findings suggest that screening people with hemophilia for diabetes and hypertension might have benefits.
September 19, 2022
An analysis found that a single dose of gene therapy would be more cost-effective than on-demand or prophylaxis factor replacement in 92% of cases.
September 08, 2022
Three gene therapies in late-stage development are designed to supply working copies of genes that people with hemophilia are missing. They may be one-time, curative treatments, but the seven-figure price tags will be an issue.
August 19, 2022
Lack of blood clotting may afford some protection against common cardiovascular disease events, such as ischemic stroke.